MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04528nas a22003017a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20220713141517.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
m|||||r|||| 00| 0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
ta |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
171219t2020 sp ||||| |||| 00| 0 spa | |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0211-5638 |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
Salus Infirmorum |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Diferencias entre pacientes con EPOC no adherentes y adherentes al tratamiento farmacológico según la GOLD 2018 en variables clínicas, los índices CODEX, COTE y BODE = |
| Remainder of title |
Differences in clinical variables, and CODEX, COTE and BODE indices between patients with COPD non-adherent and adherent to the pharmacological treatment according to GOLD 2018 / |
| Statement of responsibility, etc. |
J. Betancourt-Peña, J. Rodríguez-Castro y D.A. Escobar-Vidal |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Este artículo se encuentra disponible en su edición impresa. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliografía: p.31-32 |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Introducción La enfermedad pulmonar obstructiva crónica (EPOC), se caracteriza por la limitación al flujo aéreo crónica que genera síntomas como disnea, tos y sibilancias. La GOLD 2018 plantea estrategias de tratamiento farmacológico. Sin embargo, la adherencia es baja. Las diferencias entre pacientes adherentes y no adherentes no están claramente establecidas, debido a que podría existir una relación inversa entre la adherencia y las exacerbaciones.<br/><br/>Objetivo Determinar las diferencias entre pacientes adherentes y no adherentes al tratamiento farmacológico propuesto por la GOLD 2018 en variables clínicas, índices CODEX, COTE y BODE.<br/><br/>Métodos Estudio de tipo transversal, se incluyeron 126 pacientes con diagnóstico de EPOC entre enero y septiembre de 2018. Divididos en dos grupos: adherentes (EPOC-A) y no adherentes (EPOC-NA) teniendo en cuenta el tratamiento farmacológico de la GOLD 2018.<br/><br/>Resultados Setenta y nueve pacientes (EPOC-NA) y 50 (EPOC-A), el 61% pertenecían al género masculino y el 39% restante al género femenino. La edad promedio fue de 70,62 ± (8,290), la evaluación de aspectos de la GOLD, la mayoría de los pacientes adherentes pertenecen al grupo D y los no adherentes al grupo B; obteniéndose un valor p=0,004. En cuanto a los días hospitalizados, los pacientes adherentes permanecieron más días hospitalizados con una media de 11,32 ± (13,39) respecto a los no adherentes que tenían menos días 7,68 ± (13,13); valor p=0,031.<br/><br/>Conclusión Los pacientes adherentes al tratamiento farmacológico de la GOLD 2018 visitan más urgencias y presentan mayor número de exacerbaciones, lo cual se refleja en un aumento en la probabilidad de muerte. |
| 520 8# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background Chronic obstructive pulmonary disease (COPD) is characterized by the chronic limitation of airflow that generates symptoms such as dyspnoea, coughing, and wheezing. The GOLD 2018 proposes pharmacological treatment strategies. However, adherence is low. The differences between adherent and non-adherent patients are not clearly established, although there could be an inverse relationship between adherence and exacerbations.<br/><br/>Objective To determine the differences between adherent and non-adherent patients to the pharmacological treatment proposed by GOLD 2018 in clinical variables, as well as the CODEX, COTE, and BODE indices.<br/><br/>Methods Cross-sectional study was conducted on 126 patients diagnosed with COPD between January and September 2018. They were divided into two groups: adherent (COPD-A) and non-adherent (COPD-NA), taking into account the pharmacological treatment of GOLD 2018.<br/><br/>Results The groups included 79 patients inCOPD-NA, and 50 in COPD-A), of which 61% were males and 39% females. The mean age was 70.62 ± (8.29. The majority of adherent patients belonged to GOLD group D, and the non-adherent to GOLD group B (P=.004). As regards days hospitalised, the adherent patients spent more days in hospital, with a mean of 11.32 ± (13.39) days, compared to non-adherent patients with fewer days 7.68 ± (13.13); P =.031.<br/><br/>Conclusion Patients adhering to the pharmacological treatment of GOLD 2018 make more emergency department visits and present with a greater number of exacerbations, and is reflected in an increase in the probability of mortality. |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
enfermedad pulmonar obstructiva crónica |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
tratamiento farmacológico |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
hospitalización |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
adherencia |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
pulmonary disease |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
drug therapy |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
hospitalisation |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
medication adherence |
| 773 ## - HOST ITEM ENTRY |
|---|
| Related parts |
-- 2020, v. 42, n. 1, p. 24-32 |
| Title |
Fisioterapia |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Universal Decimal Classification |
| Koha item type |
Artículo de revista |
